Today’s AI Top Pick: UPST

7/6/2026 · Short Squeeze High Growth screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

View the live UPST price forecast →

Today's pick · Short Squeeze High GrowthUPSTBUY NOW8.4 / 107/6/2026

Upstart is the cleanest confluence of the screen's thesis (32.75% short float, RSI 59.3, epsNextY +103.35%, salesYoY +57.69%) with a forecast tape that actually confirms across timeframes. On the 1d, fc_short +29.13%, fc_mid +35.29%, fc_long +13.66%; on the 1wk, fc_short +3.84%, fc_mid +44.16%, fc_long +139.76%. That is genuine multi-timeframe agreement pointing higher, backed by kronos bullish_prob = 1.0 and near_term_bullish = 0.8 — few names in this pool have both. Critically, price is NOT pinned to the highs: 1h pos_in_21bar_range is only 16.21% and 1d is 89.55% (not yet 100% like DAVE, SEZL, PAR, CELH). You are buying into a stock that is still working, not one that already blew off. Fundamentals are good enough to justify the squeeze: PEG 0.83, fwdPe 18.96 (vs. trailing PE 89 — earnings are turning), gross margin 97.87%, and ROE 7.01% climbing. It is not the cheapest name (PGY is much cheaper) or the most profitable (CRK), but PGY's own forecast tape is deteriorating (1d fc_long −15.8%, 1wk fc_mid −22.68%) and CRK just got hit with a Goldman Sell and Morgan Stanley PT cut to $16 — both undercut their strong fundamentals. UPST's newsflow, by contrast, is a Seeking Alpha 'Reiterate Buy' on July 3 citing a promising recovery setup. The 32.75% short float is the kicker. With RSI still only 59.3 (nowhere near overbought like DAVE at 78 or SEZL at 80), positive multi-TF forecasts, and an established negative-sentiment overhang, this is exactly the profile where a squeeze can extend. You get asymmetric upside (1wk fc_long +139.76%) without the 'top of the range' chase risk that plagues DAVE, SEZL, CELH, PAR and DLO. Waiting is the wrong move here: the 1d forecast is +29% short-term, the setup is intact but not extended, and there is no landmine headline. If you wait for a deeper pullback, you likely miss it as shorts start covering into positive analyst tone.

UPST forecast chart
Entry zone
$34.00–$35.50 (current $35.11; add on any dip to the $34 handle where 1h dd_from_21bar_high = -4.67%)
Stop loss
$31.00 (below the 1wk dd_from_21bar_high -8.18% level; ~11% risk)
First target
$42–$45 (roughly the 1d fc_short +29% projection)
Longer target
$55–$65 (aligns with 1wk fc_mid +44% and analyst squeeze extension)
Risks
  • Consumer credit / funding-market risk — UPST is credit-sensitive; a macro credit shock would compress the thesis (Zacks noted July 2 that outlook 'hinges on funding')
  • Q2 2026 could be 'lumpy' per the July 3 Seeking Alpha piece — a soft print could reset the squeeze
  • Valuation still elevated: trailing PE 89.78, PS 2.92, debtEq 2.7; profit margin only 4.34%
  • 1h forecast is actually negative (fc_mid -15.47%, fc_long -8.89%) — near-term intraday chop is likely; the higher TFs are what carry the trade
  • 32.75% short float cuts both ways — if the tape rolls over, forced-cover buyers become forced sellers fast
Honorable mentions
CRKBest pure-value name in the pool: PE 6.94, PEG 0.38, profitMargin 30.99%, ROE 25.44%, and sitting at only 16.46% of its 1wk range (real pullback entry, not a chase). 1d forecasts +27.48%/+26.89%, bullish_prob 1.0. Would be #1 if not for the June 30 Goldman Sell reiteration and Morgan Stanley PT cut to $16 — the analyst tape actively fights the thesis.
CELHFundamentals-plus-narrative pick: fund_score 6.5, salesYoY +123.34%, PEG 0.87, targetUpside +78.9%, and 1d forecasts all +22–26%. 1wk position only 15.36% of range means room to run. Held back by near_term_bullish 0.2 and 1d pos 100% — I want to buy this on a dip to $31, not at $33.50.
Full ranking (30)
#SymbolVerdictScoreRead
1UPSTBUY NOW8.4Multi-TF forecasts all up (1d +29%/+35%, 1wk +44%/+140%), 32.75% short float, positive analyst note, not yet extended.
2CRKBUY NOW7.8Cheap (PE 6.94, PEG 0.38), deep in 1wk range (16%), strong 1d forecasts, but Goldman Sell is a real overhang.
3CELHBUY PULLBACK7.2Strong forecasts (1d all +22-26%, 1wk mid +40%) and momentum reclaim, but 1d pos 100% — wait for $31 handle.
4PGYBUY PULLBACK6.8Best fundamentals in the pool (fund_score 8, PEG 0.21, fwdPe 9.15) but forecast tape is weak (1wk fc_mid -22.68%).
5VSTMBUY NOW6.51wk fc_long +111%, pos 24% of 1wk range, positive trial catalyst — high-variance speculative buy.
6FOURBUY PULLBACK6.3fwdPe 7.55, PEG 0.51 and 1d forecasts +19-27%, but 1d pos 99% and near-term prob only 0.2.
7DUOLBUY PULLBACK6.01d fc +26/+53/+75%, 1wk +73% long, but DA Davidson flagged DAU stall and targetUpside is -16%.
8PARBUY PULLBACK5.81wk fc_mid +143% and bullish_prob 1.0, but pos 100% on 1h/4h/1d — pure chase entry today.
9BIRKWAIT5.2Solid fundamentals (operMargin 24.5%, PEG 1.04) but forecasts mostly negative into mid-horizon.
10WGSWAIT4.91d fc +16/+24% and 4h fc_long +121% but fund_score -1.75 and 1d pos 99.55%.
11SAILWAIT4.6Fresh Entro acquisition and Q2 guide reiteration is positive but forecast tape is mixed and bullish_prob is null.
12KLARWAIT4.4Google court-win catalyst + DB PT raise is nice, but 1d/1h forecasts are negative and epsNextY of 288% looks like a low-base illusion.
13STIMWAIT4.21wk fc_mid/long +129/+131% but micro-cap ($98M) with no fresh news since May earnings.
14SNDXWAIT4.0Positive Revuforj data but 1d/1wk forecasts skew negative (fc_mid -20/-25%).
15KULRWAIT3.91wk fc_long +137% but 1d down -15% and profitMargin -383%; pure lotto ticket.
16IOVAWAIT3.7Recent FDA nod but daily/4h forecasts negative and near_term_bullish only 0.6.
17HROWWAIT3.5BYOOVIZ launch is a positive catalyst but 1wk forecasts all deeply negative (-20 to -43%).
18DFDVWAIT3.41h/4h/1d forecasts positive but 1wk fc_long -61% and ROE -2398% — treasury-strategy micro-cap.
19BETRWAIT3.21wk fc_long +156% and BTIG Buy, but debtEq 83 and Seeking Alpha 'Unattractive' note is a caution.
20TEMWAIT3.0Fund_score -2.5, only modest 1d/1wk forecast lift; already jumped 19%.
21DLOAVOID2.8Great fundamentals wasted — 1d and 1wk pos 100%, forecasts mostly -10 to -20%, RSI 75.
22NTLAAVOID2.61d/4h forecasts -21 to -53%; 1wk +128% long is too far out to trade off today.
23TGTXAVOID2.41d fc_short -36.8%, all TF forecasts negative, targetUpside -3% — a rollover setup.
24NTSTAVOID2.2All timeframe forecasts negative; PE 180.95 with 20.5% sales growth doesn't justify it.
25HIMSAVOID2.0Fund_score -5, targetUpside -20.5%, fwdPe 78.94; momentum name past its window.
26IBRXAVOID1.9Up 377% YTD, 1d fc -58%, insider selling — classic distribution profile.
27DAVEAVOID1.7RSI 78, YTD +75%, 1d fc_short -42.6%, 1wk fc_long -58% — textbook 'don't chase'.
28SEZLAVOID1.5RSI 80.52, YTD +189%, 1wk fc_long -92%, targetUpside -22.7% — the setup is broken.
29PGENAVOID1.41wk fc_long -83%, profitMargin -1213%, no forecasts alignment despite FDA news.
30LCIDAVOID1.2Europe layoffs headline overnight, delivery weakness, no forecast data — do not touch.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord